September 21, 2026
A draft executive order to centralize NIH grant approvals under the White House moved roughly 500 billion dollars in market value.
What happened
The White House is drafting an executive order to take over NIH grant approvals, according to The Hill. The report raised concerns that research funding distribution could be altered. The news moved about 500 billion dollars of market value.
Why it matters
If grant approval moves from scientific reviewers to political appointees, the flow of tens of billions in research dollars could shift toward favored fields or institutions and away from others. That would remake the economics of drug development, university labs, and biotech startups whose valuations rest on future NIH-backed work.
The case against
The order may never be signed, or it could emerge with safeguards that preserve peer review. Even if signed, Congress controls the NIH budget and could blunt any radical shift in funding. Markets may be pricing in a worst case that does not materialize.
What settles it
Whether the executive order is formally signed and, if so, the extent to which it replaces or merely overlays the existing peer review process.